Designed affinity ligands to capture human serum albumin

Area of Science:

• Biochemistry
• Affinity Chromatography
• Drug Discovery

Background:

• Human serum albumin (HSA) is a crucial therapeutic agent and biomarker with growing demand.
• Existing methods for HSA purification face challenges in efficiency and yield.
• Understanding protein-ligand interactions is key to developing novel purification strategies.

Purpose of the Study:

• To design and screen a library of triazine-based ligands for efficient human serum albumin (HSA) binding.
• To identify lead ligands for the development of improved HSA purification methods.
• To optimize binding and elution conditions for HSA purification from human plasma.

Main Methods:

• Rational design and combinatorial synthesis of 64 triazine-based ligands.
• Screening of ligands for HSA binding affinity at physiological conditions.
• Optimization of binding and elution parameters for affinity chromatography using selected lead ligands.

Main Results:

• Two lead ligands, A3A2 and A6A5, demonstrated significant HSA binding (>50% bound) and high enrichment factors.
• The A6A5 adsorbent achieved a highly pure HSA sample (98% purity) with complete recovery (100% yield).
• Optimized mild binding and elution conditions were established for the A6A5 ligand.

Conclusions:

• Triazine-based ligands represent a promising class of molecules for efficient HSA capture.
• The A6A5 ligand offers a robust and effective solution for purifying HSA from human plasma.
• This study provides a foundation for developing advanced affinity chromatography materials for therapeutic protein purification.